medRxiv preprint doi: https://doi.org/10.1101/2020.06.05.20123554; this version posted October 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The Role of Vitamin D in The Age of COVID-19:
A Systematic Review and Meta-Analysis

Roya Ghasemian[1], Amir Shamshirian[2,3]*, Keyvan Heydari[3,4], Mohammad Malekan[4], Reza Alizadeh-Navaei[3], Mohammad Ali Ebrahimzadeh[5], Hamed Jafarpour[4], Arash Rezaei Shahmirzadi[8], Mehrdad Khodabandeh[9], Benyamin Seyfari[10], Alireza Motamedzadeh[11], Ehsan Dadgostar[12], Marzieh Aalinezhad[13], Meghdad Sedaghat[14], Morteza Behnamfar[15], Anahita Asadi[5], Bahman Zarandi[16], Nazanin Razzaghi[8], Vahid Yaghoubi Naei[17], Amirhossein Hessami[2], Soheil Azizi[18], Ali Reza Mohseni[18,19], Danial Shamshirian[20]*

1. Antimicrobial Resistance Research Center, Department of Infectious Diseases, Mazandaran University of Medical Sciences, Sari, Iran.

2. Department of Medical Laboratory Sciences, Student Research Committee, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran.

3. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

4. Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

5. Pharmaceutical Sciences Research Center, Department of Medicinal Chemistry, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.

6. School of Biomedical Engineering, University of Technology Sydney, Sydney, Ultimo, NSW, 2007, Australia.

7. Institute of Molecular Medicine, Sechenov First Moscow State University, Moscow, 119991, Russia.

8. Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran.

9. Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, Iran University of Medical Sciences, Tehran, Iran.

10. Department of Surgery, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

11. Department of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

12. Halal Research Center of IRI, FDA, Tehran, Iran.

13. Department of Radiology, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

14. Department of Internal Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

15. Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.

16. Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.

17. Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

18. Department of Medical Laboratory Sciences, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran.

19. Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.

20. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Corresponding authors:
1. Danial Shamshirian, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
E-Mail: shamshirian@sbmu.ac.ir
Tel: +98 912 640 6146
2. Amir Shamshirian; Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
E-Mail: shamshirian.amir@gmail.com
Tel: +98 915 187 2961

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.05.20123554; this version posted October 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The Role of Vitamin D in The Age of COVID-19:
A Systematic Review and Meta-Analysis

Abstract

Background: Evidence recommends that vitamin D might be a crucial supportive agent for the immune system, mainly in cytokine response regulation against COVID-19. Hence, we carried out a systematic review and meta-analysis in order to maximize the use of everything that exists about the role of vitamin D in the COVID-19.

Methods: A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, and Google Scholar (intitle) as well as preprint database of medRxiv, bioRxiv, Research Square, preprints.org, and search engine of ScienceDirect up to October 10, 2020. Studies focused on the role of vitamin D in confirmed COVID-19 patients were entered into the systematic review.

Results: Sixteen studies containing 4922 participants entered into the meta-analysis. The meta-analysis indicated that 48% of COVID-19 patients were suffering from vitamin D deficiency (95% CI, 29%-67%), and in 41% of patients, levels of vitamin D were insufficient (95% CI, 10%-82%). The serum 25-hydroxyvitamin D concentration was 18 ng/mL among all COVID-19 patients (95% CI, 13-24). Co-morbidities frequency in COVID-19 patients were as follows: 7.4% cancer, 27.1% chronic kidney disease, 30.4% cardiovascular diseases, 5.1% dementia, 14.5% depression/anxiety, 32.1% diabetes, 47.4% hypertension, 22.0% obesity and 17.5% respiratory diseases. Reported ethnic groups in studies were 1.0% Afro-Caribbean, 10.3% Asian, and 92.1% Caucasian.

Conclusion:

This study found that the mean serum 25-hydroxyvitamin D level was low in all COVID-19 patients, and most of them were suffering from vitamin D deficiency/insufficiency. The Caucasian was the dominant ethnic group, and the most frequent co-morbidities in COVID-19 patients were hypertension, cardiovascular diseases, chronic kidney disease, diabetes, obesity, and respiratory diseases, which might be affected by vitamin D deficiency directly or indirectly.

Keywords: Pandemic, 2019-nCoV, Coronavirus Outbreaks, SARS-CoV-2, Vitamin D, 25-hydroxyvitamin D, 25(OH)D.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.05.20123554; this version posted October 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction:

Following the emergence of a novel coronavirus from Wuhan, China, in December 2019, the respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the whole world and is declared a pandemic by World Health Organization (WHO) on March 26, 2020(1). According to Worldometer metrics, this novel virus has been responsible for approximately 37,754,464 infections, of which 28,361,239 cases are recovered, and 1,081,500 patients have died worldwide up to October 12, 2020.

After months of medical communities' efforts, there is still no specific prevention and treatment approach against the Coronavirus Disease 2019 (COVID-19). Also, a competition of pandemic with infodemic has led to many controversies and challenges globally. In this regard, one of the hottest topics these days is the role of Vitamin D in the prevention or treatment of COVID-19. Several functions, such as modulating the adaptive immune system and cell-mediated immunity, as well as an increase of antioxidative-related genes expression, have been proven for Vitamin D as an adjuvant in the prevention and treatment of acute respiratory infections (2, 3). According to available investigations, it seems that such functions lead to cytokine storm suppression and avoid Acute Respiratory Distress Syndrome (ARDS), which has been studied on other pandemics and infectious diseases in recent years (4-6).

To the best of our knowledge, unfortunately, after several months, there is no adequate high-quality data on different treatment regimens, which raises questions about gaps in scientific works. On this occasion, when there is an essential need for controlled randomized trials, it is surprising to see only observational studies without a control group or non-randomized controlled studies with retrospective nature covering a small number of patients. The same issue is debatable for 25-hydroxyvitamin D (25(OH)D); hence, concerning all of the limitations and analyze difficulties, we carried out a rapid systematic review and meta-analysis to try for maximizing the use of everything that exists about the role of this vitamin in the COVID-19.

Methods:

Search Strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was considered for the study plan. A systematic search through databases of PubMed, Scopus, Embase, Cochrane Library, Web of Science, and Google Scholar (intitle), as well as preprint database of medRxiv, bioRxiv, Research Square, preprints.org, and search engine of ScienceDirect, was done up to October 10, 2020. Moreover, to obtain more data, we considered gray literature and references of eligible papers. The search strategy included all MeSH terms and free keywords found for COVID-19, SARS-CoV-2, and Vitamin D. There was no time/location/ language limitation in this search.

Criteria study selection

Four researchers have screened and selected the papers independently, and the supervisor solved the disagreements. Studies met the following criteria included in the meta-analysis: 1) comparative or non-comparative studies with retrospective or prospective nature; and 2) studies reported the role of vitamin D in confirmed COVID-19 patients. Studies were excluded if they were: 1) *in vitro* studies, experimental studies, reviews, 2) duplicate publications.

Data extraction & quality assessment

Two researchers (H.J and M.M) have evaluated the papers' quality assessment and extracted data from selected papers. The supervisor (D.Sh) resolved any disagreements in this step. The data extraction checklist included the name of the first author, publication year, region of study, number of patients, co-morbidity, vitamin D Status, serum 25-hydroxyvitamin D levels, ethnicity, mean age, medication dosage, treatment duration, adverse effects, radiological

medRxiv preprint doi: https://doi.org/10.1101/2020.06.05.20123554; this version posted October 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

results, and mortality. The modified Newcastle-Ottawa Scale (NOS) checklist for cross-sectional studies was used to value the studies concerning various aspects of the methodology and study process.

Hypothetical strategy

In this case, according to most of the studies, vitamin D cut-off points were considered as follows:

- Vitamin D sufficiency: 25(OH)D concentration greater than 30 ng/mL
- Vitamin D insufficiency: 25(OH)D concentration of 20 to 30 ng/mL
- Vitamin D deficiency: 25(OH)D level less than 20 ng/mL

Targeted outcomes

1) Frequency of Vitamin D status in COVID-19 patients; 2) Mean 25(OH)D concentration; 3) Association between Vitamin D deficiency and COVID-19; 4) Co-morbidity frequency; 5) Ethnicity frequency.

Heterogeneity assessment

I-square (I^2) statistic was used for heterogeneity evaluation. Following Cochrane Handbook for Systematic Reviews of Interventions (7), the I^2 was interpreted as follows: "*0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. The importance of the observed value of I^2 depends on (i) magnitude and direction of effects and (ii) strength of evidence for heterogeneity (e.g., P-value from the chi-squared test, or a confidence interval for I^2).*" Thus, the random-effects model was used for pooling the outcomes in case of heterogeneity; otherwise, the inverse variance fixed-effect model was used. Forest plots were presented to visualize the degree of variation between studies.

Data analysis

Meta-analysis was performed using Comprehensive Meta-Analysis (CMA) *v*. 2.2.064 software. The pooling of effect sizes was done with 95% Confident Interval (CI). The fixed/random-effects model was used according to heterogeneities. In the case of zero frequency, the correction value of 0.1 was used.

Publication bias & sensitivity analysis

Begg's and Egger's tests and the funnel plot were used for publication bias evaluation. A *P*-value of less than 0.05 was considered as statistically significant.

Results

Study selection process

The first search through databases resulted in 1030 papers. After removing duplicated papers and first step screening based on title and abstract, 89 papers were assessed for eligibility. Finally, 16 articles were entered into the meta-analysis. PRISMA flow diagram for the study selection process is presented in Figure 1.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.05.20123554; this version posted October 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1.PRISMA flow diagram for the study selection process

Study characteristics

Among the 16 studies included in the meta-analysis, all were designed in retrospective nature, except for one study in prospective nature. The studies' sample size ranged from 10 to 2903, including 4922 participants. Characteristics of studies entered into the systematic review presented in Table 1.

Table 1. Characteristics of studies entered into the systematic review

Study	Country	Study design	No. of Patients (male/female)	Controls (male/female)	Mean (± SD) Median (IQR) Age	Co-morbidity	Vitamin D Status			Ethnicity		
							N	**I**	**D**	CS	AC	O
De Smet *et al.* 2020 (8)	Belgium	Single-center observational study	186 (109/77)	2717 (999/1718)	69 (52-80)	-	77	-	109	-	-	-
Nicola *et al.* 2020 (9)	Italy	Retrospective cohort study	112 (52/60)	-	47.2 (± 16.4)	-	-	-	-	-	-	-
Macaya *et al.* 2020 (10)	Spain	Retrospective cohort study	80 (35/45)	-	67.65 (50-84)	Hypertension: 50 Diabetes mellitus: 32 Cardiac disease: 19	-	-	45	-	-	-
Karahan *et al.* 2020 (11)	Turkey	Retrospective cohort study	149 (81/68)	-	63.5 (± 15.3)	Coronary artery disease: 32 Hypertension: 85 Dyslipidemia: 39 Diabetes mellitus: 61 Cerebrovascular accident: 9 COPD: 15 Malignancy: 23 CKD: 29 Chronic atrial fibrillation: 15 Congestive heart failure: 18 Acute kidney injury: 16	12	34	103	-	-	-
Faniyi *et al.* 2020 (12)	UK	Prospective cohort study	214	-	-	-	170	-	44	-	-	-
Im *et al.* 2020 (13)	South Korea	Retrospective cross sectional	50	150	57.5 (34.5-68.0)	-	13	-	37	-	-	-
Lau *et al.* 2020 (14)	U.S.	Retrospective cross sectional	20 (9/11)	-	65.2	Hypertension: 15 Diabetes: 7	2	8	10	5	15	-
Maghbooli *et al.* 2020 (15)	Iran	Retrospective cross sectional	235	-	58.72(±15.2) *mean	Diabetes: 86 Hypertension: 104 Respiratory disease: 72 Cancer: 2	77	-	-	-	-	-
Cuñat *et al.* 2020 (16)	Spain	Retrospective analysis	17 (10/7)	-	64.94	CKD: 2	-	-	17	-	-	-
Baktash *et al.* 2020 (17)	UK	Prospective cohort study	70 (42/28)	-	≥65	Hypertension: 34 Diabetes mellitus: 26 Ischemic heart disease: 15 Chronic respiratory disease: 13 Heart failure: 12 Stroke: 9 Dementia: 6 Chronic kidney disease: 16 Atrial fibrillation: 14 Cancer: 3 Endocrinological disease: 3	31	-	39	50	-	20
Pinzon *et al.* 2020 (18)	Indonesia	Case Series and Recent Literature Review	10 (5/5)	-	49.6	Hypertension: 4 Diabetes: 1 COPD: 1 Stroke: 1	0	1	9	-	-	-
Meltzer *et al.* 2020 (19)	U.S.	Retrospective cohort study	71	-	-	Hypertension:261 Diabetes:137 COPD:117 Pulmonary circulation disorders: 20 Depression :119 CKD:116 Liver disease :56 Comorbidities with immunosuppression: 105	39	-	32	-	-	-
Faul *et al.* 2020 (20)	Ireland	Retrospective cross sectional	33 (33/0)	-	≥40	-	21	-	12	33	-	-
Merzon *et al.* 2020 (21)	Israel	Retrospective cohort study	782 (385/397)	7,025 (2,849, 4,176)	35.58	Depression/Anxiety: 73 Schizophrenia: 15 Dementia: 27 Diabetes mellitus: 154 Hypertension: 174 Cardiovascular disease: 78 Chronic lung disorders: 66 Obesity: 235	79	598	105	-	-	-

Panagiotou *et al.* 2020 (22)	UK	Retrospective cross sectional	134 (73/61)	-	-	Hypertension: 56 Diabetes: 38 Obesity: 14 Malignancy: 15 Respiratory: 42 Cardiovascular disease: 20 Kidney and Liver diseases: 19	-	-	44	132	1	1
Carpagnano *et al.* 2020 (23)	Italy	Retrospective cohort study	42 (30/12)	-	65 (±13) *mean	Hypertension: 26 Cardiovascular disease: 16 CKD: 16 Diabetes type II: 11 Cerebrovascular disease: 5 Psychosis, depression, anxiety: 10 Malignancy: 5 COPD: 5 Asthma: 2	8	11	23	-	-	-

SD: Standard deviation, IQR: Interquartile range, U.S.: United States, UK: United Kingdom, N: Normal, I: Insufficient, D: Deficient, CS: Caucasian, AC: Afro-Caribbean, O: Other, COPD: Chronic obstructive pulmonary disease, CKD: Chronic Kidney Disease

Quality assessment

Results of quality assessment for studies entered into meta-analysis based on a modified version of the NOS tool for cross-sectional studies were fair.

Publication bias

Begg's and Egger's tests in effect size meta-analysis showed non-significant and significant publication bias for vitamin D status (P_B=0.75; P_E=0.02, respectively). The funnel plot for publication bias of studies presented in Fig. 2.



Figure 2. Funnel plot for publication bias of studies

Meta-analysis findings

Frequency of Vitamin D status in COVID-19 patients

The meta-analysis of event rates in peer reviewed papers showed that 48% of COVID-19 patients were suffering from vitamin D deficiency (95% CI, 29%-67%), and in 41% of patients, levels of vitamin D were lower than the normal range (95% CI, 10%-82%) (Fig. 3). To maximize the use of everything that exists, the inclusion of pre-prints data to the meta-analysis resulted in a 48% (95% CI, 33%-63%) deficiency and 29% (95% CI, 8%-65%) insufficiency in vitamin D status (Supplementary Fig. 1).



Figure 3. Forest plot for pooling events of vitamin D status

Mean serum 25-hydroxyvitamin D concentration

The meta-analysis of mean 25(OH)D concentration was 18 ng/mL among all COVID-19 patients (95% CI, 13-24), 18.20 ng/mL in severe cases (95% CI, 1-35) and 26 ng/mL in non-severe cases (95% CI, 23.89-28.70) (Fig. 4). Also, by including pre-prints, meta-analysis resulted in 20 ng/mL 25(OH)D in all cases, 18 ng/mL and 26 ng/mL in non-severe and severe cases, respectively (Supplementary Fig. 2).



Figure 4. Forest plot for pooling mean 25(OH)D concentrations

Co-morbidities

Meta-analysis of available data on co-morbidities frequency in COVID-19 patients were as follows: in non-severe cases, 13.0% cancer, 11.8% chronic kidney disease (CKD), 15.4% cardiovascular diseases (CVD), 30.3% diabetes and 35.7% hypertension (HTN), 12.9% obesity, and 18.3% respiratory diseases (Supplementary Figures 3); in severe cases, 12.6% cancer, 34.2% CKD, 30.4% CVD, 41.9% diabetes and 72.6% HTN, 26.4% obesity, and 17.4% respiratory diseases (Supplementary Figures 4); in overall, 7.4% cancer, 27.1% CKD, 30.4% CVD, 5.1% dementia, 14.5% depression/anxiety, 32.1% diabetes, 47.4% HTN, 22.0% obesity and 17.5% respiratory diseases. Frequency of co-morbidities by including pre-prints is presented in Supplementary Figures 5 to 7.

Study name	Subgroup within study	Event rate	Lower limit	Upper limit	Z-Value	p-Value	Total
G. E. Carpagnano	Cancer	0.119	0.050	0.256	-4.201	0.000	5 / 42
G. Panagiotou	Cancer	0.112	0.069	0.177	-7.559	0.000	15 / 134
S. Karahan	Cancer	0.154	0.105	0.222	-7.501	0.000	23 / 149
V. Baktash	Cancer	0.043	0.014	0.125	-5.263	0.000	3 / 70
Z. Maghbooli	Cancer	0.009	0.002	0.033	-6.700	0.000	2 / 235
		0.074	0.035	0.147	-6.405	0.000	
F. Macaya	CKD	0.325	0.232	0.435	-3.062	0.002	26 / 80
G. E. Carpagnano	CKD	0.381	0.248	0.534	-1.528	0.127	16 / 42
S. Karahan	CKD	0.195	0.139	0.266	-6.863	0.000	29 / 149
V. Baktash	CKD	0.229	0.145	0.341	-4.273	0.000	16 / 70
		0.271	0.195	0.362	-4.572	0.000	
E. Merzon	CVD	0.100	0.081	0.123	-18.436	0.000	78 / 782
F. Macaya	CVD	0.238	0.157	0.343	-4.440	0.000	19 / 80
G. E. Carpagnano	CVD	0.381	0.248	0.534	-1.528	0.127	16 / 42
G. Panagiotou	CVD	0.149	0.098	0.220	-7.179	0.000	20 / 134
S. Karahan	CVD	0.436	0.359	0.517	-1.552	0.121	65 / 149
V. Baktash	CVD	0.714	0.598	0.808	3.463	0.001	50 / 70
		0.304	0.141	0.537	-1.662	0.096	
E. Merzon	Dementia	0.035	0.024	0.050	-17.006	0.000	27 / 782
V. Baktash	Dementia	0.086	0.039	0.178	-5.544	0.000	6 / 70
		0.051	0.021	0.120	-6.141	0.000	
E. Merzon	Depression/Anxiety	0.093	0.075	0.116	-18.495	0.000	73 / 782
G. E. Carpagnano	Depression/Anxiety	0.238	0.133	0.389	-3.211	0.001	10 / 42
		0.145	0.054	0.335	-3.204	0.001	
E. Merzon	Diabetes	0.197	0.171	0.226	-15.631	0.000	154 / 782
F. Macaya	Diabetes	0.400	0.299	0.510	-1.777	0.076	32 / 80
G. E. Carpagnano	Diabetes	0.262	0.151	0.414	-2.952	0.003	11 / 42
G. Panagiotou	Diabetes	0.284	0.214	0.366	-4.836	0.000	38 / 134
S. Karahan	Diabetes	0.409	0.333	0.490	-2.200	0.028	61 / 149
V. Baktash	Diabetes	0.371	0.267	0.490	-2.127	0.033	26 / 70
Z. Maghbooli	Diabetes	0.366	0.307	0.429	-4.058	0.000	86 / 235
		0.321	0.243	0.411	-3.764	0.000	
E. Merzon	Hypertension	0.223	0.195	0.253	-14.552	0.000	174 / 782
F. Macaya	Hypertension	0.625	0.515	0.724	2.212	0.027	50 / 80
G. E. Carpagnano	Hypertension	0.619	0.466	0.752	1.528	0.127	26 / 42
G. Panagiotou	Hypertension	0.418	0.337	0.503	-1.892	0.059	56 / 134
S. Karahan	Hypertension	0.570	0.490	0.648	1.715	0.086	85 / 149
V. Baktash	Hypertension	0.486	0.371	0.601	-0.239	0.811	34 / 70
Z. Maghbooli	Hypertension	0.443	0.380	0.507	-1.757	0.079	104 / 235
		0.474	0.336	0.616	-0.351	0.726	
E. Merzon	Obesity	0.301	0.269	0.334	-10.832	0.000	235 / 782
F. Macaya	Obesity	0.288	0.199	0.396	-3.674	0.000	23 / 80
G. Panagiotou	Obesity	0.104	0.063	0.169	-7.607	0.000	14 / 134
		0.220	0.122	0.365	-3.495	0.000	
E. Merzon	Respiratory disease	0.084	0.067	0.106	-18.533	0.000	66 / 782
F. Macaya	Respiratory disease	0.163	0.097	0.260	-5.411	0.000	13 / 80
G. E. Carpagnano	Respiratory disease	0.167	0.082	0.310	-3.887	0.000	7 / 42
G. Panagiotou	Respiratory disease	0.313	0.241	0.397	-4.211	0.000	42 / 134
S. Karahan	Respiratory disease	0.101	0.062	0.160	-8.043	0.000	15 / 149
V. Baktash	Respiratory disease	0.186	0.111	0.294	-4.809	0.000	13 / 70
Z. Maghbooli	Respiratory disease	0.306	0.251	0.368	-5.774	0.000	72 / 235
		0.175	0.103	0.281	-4.963	0.000	



Figure 5. Forest plot for pooling overall co-morbidities frequency

Ethnicity frequency

Pooling available data regarding ethnicity distribution among COVID-19 patients resulted in 1.0% Afro-Caribbean, 10.3% Asian, and 92.1% Caucasian.

Study name	Subgroup within study	Event rate	Lower limit	Upper limit	Z-Value	p-Value	Total
G. Panagiotou	Afro-Caribbean	0.007	0.001	0.051	-4.872	0.000	1 / 134
V. Baktash	Afro-Caribbean	0.014	0.002	0.094	-4.204	0.000	1 / 70
		0.010	0.003	0.040	-6.418	0.000	
G. Panagiotou	Asian	0.030	0.011	0.077	-6.858	0.000	4 / 134
V. Baktash	Asian	0.286	0.192	0.402	-3.463	0.001	20 / 70
		0.103	0.009	0.587	-1.687	0.092	
G. Panagiotou	Caucasian	0.955	0.904	0.980	7.326	0.000	128 / 134
J.L. Faul	Caucasian	0.988	0.783	0.999	2.766	0.006	33 / 33
V. Baktash	Caucasian	0.714	0.598	0.808	3.463	0.001	50 / 70
		0.921	0.630	0.987	2.504	0.012	



Figure 6. Forest plot for pooling ethnicity frequency

Discussion

Epidemiological & clinical aspects

Although comparing global statistics of COVID-19 outcomes is difficult, it is clear that the mortality rate is higher in several countries. It seems that among various factors such as age, healthcare system quality, general health status, socioeconomic status, etc. One of the underestimated factors that might be associated with COVID-19 outcome is the vitamin D status in every population. In recent years, vitamin D deficiency/insufficiency has become a global health issue, and its impact has been studied on respiratory viral infections. Most of the epidemiological studies have been reported a higher risk of developing the infection to the severe stages and death in patients with low levels of vitamin D (24-27). Besides, vitamin D clinical interventions have demonstrated a significantly reduced risk of respiratory tract infection (RTI), further proposed as a prophylactic or treatment approach against RTIs by WHO in 2017 (28-30).

Concerning all of the limitations and lack of high-quality data about the relation of vitamin D status and COVID-19 after several months, we have conducted this systematic review and meta-analysis to maximize the use of every available data, which would give us an overview toward further studies like what we have done recently on the effectiveness of hydroxychloroquine in COVID-19 patients (31), which have underestimated first, but the value was revealed after a while.

According to available data entered into our meta-analysis, we could find that approximately half of the patients infected with SARS-CoV-2 were suffering from vitamin D deficiency, and this vitamin was insufficient in about 41% of them. We have also found that mean 25(OH)D levels were low (<20 ng/mL) in all COVID-19 patients. These findings are in the same line with studies that have debated the association of vitamin D and COVID-19 (32-36). Recently, Kaufman *et al*. (37), studied the relation of SARS-CoV-2 positivity rates with circulation 25(OH)D among 191,779 patients retrospectively. They found the highest SARS-CoV-2 positivity rate among patients with vitamin D deficiency (12.5%, 95% CI, 12.2-12.8%). Overall, the study indicated a significant inverse relation between SARS-CoV-2 positivity and circulating 25(OH)D levels in COVID-19 patients.

Along with all observational studies, a pilot randomized clinical trial performed by Castillo *et al.* (38) on 76 hospitalized COVID-19 patients indicated a promising result for calcifediol therapy in these individuals. In this study, high dose oral calcifediol significantly reduced the need for intensive care unit (ICU) treatment. However, due to the small sample size, more extensive, well-organized clinical trials are needed to robust and confirm this study's findings.

Additionally, in the case of vitamin D supplements' benefits against acute respiratory tract infections, Martineau *et al.* conducted a meta-analysis of randomized controlled on 10.933 participants and resulted in an inverse association between vitamin D levels and risk of acute respiratory tract infections. Thus, it can be concluded that patients with lower vitamin D levels or patients with vitamin D deficiency are at higher risk of developing the disease to the severe form (28).

Co-morbidities

After months of investigation on COVID-19, several factors such as male sex, older age, CVD, HTN, chronic lung disease, obesity, and CKD are proposed to be risk factors toward deteriorating COVID-19 patients' outcomes (39-41). Interestingly, one of the conditions that lead to most of the considered risk factors is vitamin D deficiency. Studies indicated that malignancies, diabetes, HTN, and CVDs are significantly related to vitamin D deficiency. Also, studies reported the important role of vitamin D deficiency in older males (42-44). Evidence shows that aging, physical activity, obesity, seasonal variation, less vitamin D absorption, pregnancy, thyroid disorders, prolonged use of corticosteroids, ethnicity/race can substantially affect the circulating 25(OH)D levels (45-51).

Hence, although studies reported vitamin D deficiency as one of the critical risk factors in clinical outcomes of COVID-19 patients, it seems that it can also be in a strong relationship with basic underlying risk factors and diseases in such patients.

In this case, our analyses indicated that HTN, CVDs, CKDs, diabetes, obesity, and respiratory diseases were the most frequent co-morbidities in COVID-19 patients. According to the facts mentioned above and our findings, it is plausible that both vitamin D deficiency and underlying diseases, which affect each other, may worsen the condition of these patients more than others.

Ethnicity

From the beginning of the COVID-19 pandemic, different studies have been reported probable associations between COVID-19 and the ethnicity of these patients. Most studies found that the mortality rate among black people is higher than the other ethnic groups (52-56). However, other challenges such as human resources, health care systems budgetary, poor management, etc. have to be considered among such people and low-income countries (57-59), which unavoidably affects the subject significantly. In recent years, many studies have focused on vitamin D mechanisms and status among various ethnic groups to find the roles of vitamin D and its relationships with any factors or disorders in various ethnicities (60-63).

Herein, our findings demonstrated that the most frequent ethnic group has belonged to Caucasians, followed by Asian and Afro-Caribbean. Although there is some evidence on the role of genetic variants in COVID-19 patients, the subject is still not clear enough (64, 65).

In contrast to many studies about vitamin D status in different ethnicities, Aloia *et al.* have reported that serum 25(OH)D concentration is the same in cross-racial comparison. They found an inconsistency between monoclonal and polyclonal assays for detecting vitamin D binding protein (66). Hence, the approach for considering serum 25(OH)D concentration is much important.

Vitamin D mechanisms & COVID-19

Vitamin D metabolism has been well studied throughout history. Numerous investigations indicate vitamin D's roles in reducing microbial infections through a physical barrier, natural immunity, and adaptive immunity (2, 67-72). For example, investigations on respiratory infections indicated that 25(OH)D could effectively induce the host defense peptides against bacterial or viral agents. Vitamin D insufficiency/deficiency can lead to non-communicable and infectious diseases (2, 73, 74). The other potential role of vitamin D is reducing inflammatory induced following SARS-

CoV-2 infection by suppressing inflammatory cytokines, reducing leukocytes' infiltration, interaction with polymorphonuclear leukocytes, and inhibiting complement component C3 (24, 75-79). Also, according to the available evidence for infections and malignancies (80, 81), vitamin D may enhance the serological response and $CD8^+$ T lymphocytes performance against COVID-19 when the T cells' exhaustion is related to the critical stages of the disease (82-84).

Besides, according to the revealed association of SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2), this virus can substantially downregulate the ACE2 expression, which seems to leads the COVID-19 patients to deterioration (85-87). In contrast, vitamin D affects the renin-angiotensin system pathway and promotes the expression of ACE2 (88, 89). However, since the high expression of ACE2 can be a risk factor for the severity of the disease (90), it is not yet clear enough to conclude how much vitamin D helps the condition. Hence, more evidence and trials are needed to design a treatment plan for three groups of mild, moderate, and severe patients.

It is worth noticing that the current meta-analysis includes the following limitations:1) studies entered into the meta-analysis were observational and cross-sectional; 2) There are inevitable challenges with the reliability of data due to different strategies in a testing (e.g., vitamin D measurement, COVID-19 test, etc.), various subpopulations, etc.; 3) other immunomodulatory factors (e.g., vitamin C, zinc, selenium, etc.), which might be influential in the outcome of COVID-19 patients, have not considered in included studies; and 4) type *II* statistical errors following studies with small sample size. Eventually, to overcome the limitations and bias, the study's results should be confirmed by robustly large multicentral randomized clinical trials.

Conclusion

The conditional evidence recommends that vitamin D might be a critical supportive agent for the immune system, mainly in cytokine response regulation against pathogens. In this systematic review and meta-analysis, we found that mean serum 25(OH)D level was low (<20 ng/mL) in all COVID-19 patients and most of them were suffering from vitamin D deficiency/insufficiency. The Caucasian was the dominant ethnic group, and the most frequent co-morbidities in COVID-19 patients were HTN, CVDs, CKDs, diabetes, obesity, and respiratory diseases, which might be affected by vitamin D deficiency directly or indirectly. However, further large clinical trials following comprehensive meta-analysis should be taken into account to achieve more reliable findings.

Conflict of interests

The authors declare that they have no conflict of interests.

Funding

None.

Acknowledgments:

We would like to express our appreciation to the Student Research Committee of Mazandaran University of Medical Sciences for approving this student research proposal with the code 7904.

References:

1. Organization WH. Coronavirus disease (COVID-2019) situation reports. Geneva: WHO; 2020.
2. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240-70.
3. Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. Reviews in medical virology. 2017;27(1).
4. Aranow C. Vitamin D and the immune system. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2011;59(6):881-6.
5. Goncalves-Mendes N, Talvas J, Dualé C, Guttmann A, Corbin V, Marceau G, et al. Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. Frontiers in immunology. 2019;10:65.
6. Grant WB, Giovannucci E. The possible roles of solar ultraviolet-B radiation and vitamin D in reducing case-fatality rates from the 1918-1919 influenza pandemic in the United States. Dermato-endocrinology. 2009;1(4):215-9.
7. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.0. 2nd Edition ed: John Wiley & Sons; 2019.
8. De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. medRxiv. 2020:2020.05.01.20079376.
9. Di Nicola M, Dattoli L, Moccia L, Pepe M, Janiri D, Fiorillo A, et al. Serum 25-hydroxyvitamin D levels and psychological distress symptoms in patients with affective disorders during the COVID-19 pandemic. Psychoneuroendocrinology. 2020:104869.
10. Macaya F, Espejo Paeres C, Valls A, Fernández-Ortiz A, González Del Castillo J, Martín-Sánchez J, et al. Interaction between age and vitamin D deficiency in severe COVID-19 infection. Nutr Hosp. 2020.
11. Karahan S, Katkat F. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey. The journal of nutrition, health & aging. 2020.
12. Faniyi AA, Lugg ST, Faustini SE, Webster C, Duffy JE, Hewison M, et al. Vitamin D status and seroconversion for COVID-19 in UK healthcare workers who isolated for COVID-19 like symptoms during the 2020 pandemic. medRxiv. 2020.
13. Im JH, Je YS, Baek J, Chung M-H, Kwon HY, Lee J-S. Nutritional status of patients with coronavirus disease 2019 (COVID-19). International Journal of Infectious Diseases. 2020.
14. Lau FH, Majumder R, Torabi R, Saeg F, Hoffman R, Cirillo JD, et al. Vitamin D Insufficiency is Prevalent in Severe COVID-19. medRxiv. 2020:2020.04.24.20075838.
15. Maghbooli Z, Sahraian MA, Ebrahimi M, Pazoki M, Kafan S, Tabriz HM, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PloS one. 2020;15(9):e0239799.
16. Cuñat T, Ojeda A, Calvo A. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19). Research Square. 2020.
17. Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Van den Abbeele K, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J. 2020:postgradmedj-2020-138712.
18. Pinzon RT, Angela A, Pradana AW. Vitamin D Defciency Among Patients with COVID-19 : Case Series and Recent Literature Review. Research Square. 2020.
19. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open. 2020;3(9):e2019722.
20. Faul JL, Kerley CP, Love B, O'Neill E, Cody C, Tormey W, et al. Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection. Ir Med J. 2020;113(5):84.

21. Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. The FEBS Journal. 2020;n/a(n/a).
22. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity. Clinical Endocrinology. 2020;n/a(n/a).
23. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. Research Square. 2020.
24. Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. Reviews in medical virology. 2019;29(2):e2032.
25. McNally JD, Leis K, Matheson LA, Karuananyake C, Sankaran K, Rosenberg AM. Vitamin D deficiency in young children with severe acute lower respiratory infection. Pediatric pulmonology. 2009;44(10):981-8.
26. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JLL, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127(6):e1513-e20.
27. Inamo Y, Hasegawa M, Saito K, Hayashi R, Ishikawa T, Yoshino Y, et al. Serum vitamin D concentrations and associated severity of acute lower respiratory tract infections in Japanese hospitalized children. Pediatrics international : official journal of the Japan Pediatric Society. 2011;53(2):199-201.
28. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ (Clinical research ed). 2017;356:i6583.
29. Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PloS one. 2013;8(6):e65835.
30. Aponte R, MSHN, Palacios C. Vitamin D for prevention of respiratory tract infections. WHO; e-Library of Evidence for Nutrition Actions (eLENA). 2017.
31. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, YIP GW, et al. Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis. 2020:2020.04.14.20065276.
32. Carter SJ, Baranauskas MN, Fly AD. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic. Obesity. 2020;28(7):1176-7.
33. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research. 2020;32(7):1195-8.
34. Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? American Journal of Physiology-Endocrinology and Metabolism. 2020;318(5):E589-E.
35. Molloy E, Murphy. Vitamin D, Covid-19 and Children. Ir Med J. 2020;113:64.
36. Zemb P, Bergman P, Camargo CA, Jr., Cavalier E, Cormier C, Courbebaisse M, et al. Vitamin D deficiency and the COVID-19 pandemic. Journal of global antimicrobial resistance. 2020;22:133-4.
37. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PloS one. 2020;15(9):e0239252.
38. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study". J Steroid Biochem Mol Biol. 2020;203:105751-.

39. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The lancet Diabetes & endocrinology. 2020;8(10):823-33.
40. Centers for Disease C, Prevention, editors. People with certain medical conditions2020: CDC.
41. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morbidity and mortality weekly report. 2020;69(13):382-6.
42. Orwoll E, Nielson CM, Marshall LM, Lambert L, Holton KF, Hoffman AR, et al. Vitamin D deficiency in older men. The Journal of clinical endocrinology and metabolism. 2009;94(4):1214-22.
43. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005;62(3):265-81.
44. La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D. International journal of molecular sciences. 2020;21(8).
45. Yang C-Y, Leung PSC, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):217-26.
46. Vranić L, Mikolašević I, Milić S. Vitamin D Deficiency: Consequence or Cause of Obesity? Medicina (Kaunas). 2019;55(9):541.
47. Kim D. The Role of Vitamin D in Thyroid Diseases. International journal of molecular sciences. 2017;18(9):1949.
48. Kdekian A, Alssema M, Van Der Beek EM, Greyling A, Vermeer MA, Mela DJ, et al. Impact of isocaloric exchanges of carbohydrate for fat on postprandial glucose, insulin, triglycerides, and free fatty acid responses-a systematic review and meta-analysis. European journal of clinical nutrition. 2020;74(1):1-8.
49. Cashman KD, Dowling KG, Škrabáková Z, Gonzalez-Gross M, Valtueña J, De Henauw S, et al. Vitamin D deficiency in Europe: pandemic? The American journal of clinical nutrition. 2016;103(4):1033-44.
50. Weishaar T, Rajan S, Keller B. Probability of Vitamin D Deficiency by Body Weight and Race/Ethnicity. Journal of the American Board of Family Medicine : JABFM. 2016;29(2):226-32.
51. Correia A, Azevedo Mdo S, Gondim F, Bandeira F. Ethnic aspects of vitamin D deficiency. Arquivos brasileiros de endocrinologia e metabologia. 2014;58(5):540-4.
52. Yancy CW. COVID-19 and African Americans. Jama. 2020.
53. Milam AJ, Furr-Holden D, Edwards-Johnson J, Webb B, Patton JW, Ezekwemba NC, et al. Are Clinicians Contributing to Excess African American COVID-19 Deaths? Unbeknownst to Them, They May Be. Health equity. 2020;4(1):139-41.
54. Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. Journal of racial and ethnic health disparities. 2020;7(3):398-402.
55. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? BMJ (Clinical research ed). 2020;369:m1548.
56. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes & metabolic syndrome. 2020;14(4):561-5.
57. Moszynski P. WHO report highlights Africa's health challenges. BMJ (Clinical research ed). 2006;333(7578):1088.
58. Oleribe OO, Momoh J, Uzochukwu BS, Mbofana F, Adebiyi A, Barbera T, et al. Identifying Key Challenges Facing Healthcare Systems In Africa And Potential Solutions. International journal of general medicine. 2019;12:395-403.
59. Organization WH. The African regional health report 2014: The health of the people. 2014.

60. Yuen AW, Jablonski NG. Vitamin D: in the evolution of human skin colour. Medical hypotheses. 2010;74(1):39-44.
61. Word AP, Perese F, Tseng LC, Adams-Huet B, Olsen NJ, Chong BF. 25-Hydroxyvitamin D levels in African-American and Caucasian/Hispanic subjects with cutaneous lupus erythematosus. The British journal of dermatology. 2012;166(2):372-9.
62. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. The New England journal of medicine. 2013;369(21):1991-2000.
63. Bikle D, Christakos S. New aspects of vitamin D metabolism and action - addressing the skin as source and target. Nature reviews Endocrinology. 2020;16(4):234-52.
64. Darbeheshti F, Rezaei N. Genetic predisposition models to COVID-19 infection. Medical hypotheses. 2020;142:109818.
65. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European journal of human genetics : EJHG. 2020;28(6):715-8.
66. Aloia J, Mikhail M, Dhaliwal R, Shieh A, Usera G, Stolberg A, et al. Free 25(OH)D and the Vitamin D Paradox in African Americans. The Journal of clinical endocrinology and metabolism. 2015;100(9):3356-63.
67. Holick MF. Vitamin D deficiency. The New England journal of medicine. 2007;357(3):266-81.
68. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76(3):315-25.
69. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2011;50(3):194-200.
70. Abhimanyu, Coussens AK. The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology. 2017;16(3):314-38.
71. Rondanelli M, Miccono A, Lamburghini S, Avanzato I, Riva A, Allegrini P, et al. Self-Care for Common Colds: The Pivotal Role of Vitamin D, Vitamin C, Zinc, and Echinacea in Three Main Immune Interactive Clusters (Physical Barriers, Innate and Adaptive Immunity) Involved during an Episode of Common Colds-Practical Advice on Dosages and on the Time to Take These Nutrients/Botanicals in order to Prevent or Treat Common Colds. Evidence-based complementary and alternative medicine : eCAM. 2018;2018:5813095.
72. Grant WB, Boucher BJ. Yes, vitamin D can be a magic bullet. Clinical Nutrition. 2020;39(5):1627.
73. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. Journal of immunology (Baltimore, Md : 1950). 2008;181(10):7090-9.
74. Olliver M, Spelmink L, Hiew J, Meyer-Hoffert U, Henriques-Normark B, Bergman P. Immunomodulatory effects of vitamin D on innate and adaptive immune responses to Streptococcus pneumoniae. The Journal of infectious diseases. 2013;208(9):1474-81.
75. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4):988.
76. Xu H, Soruri A, Gieseler RKH, Peters JH. 1, 25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scandinavian journal of immunology. 1993;38(6):535-40.

77. Hirsch D, Archer FE, Joshi-Kale M, Vetrano AM, Weinberger B. Decreased anti-inflammatory responses to vitamin D in neonatal neutrophils. Mediators of inflammation. 2011;2011.
78. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nature reviews Immunology. 2020;20(6):343-4.
79. Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio. 2018;9(5).
80. Karkeni E, Morin SO, Bou Tayeh B, Goubard A, Josselin E, Castellano R, et al. Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer. Frontiers in immunology. 2019;10:1307.
81. Chadha MK, Fakih M, Muindi J, Tian L, Mashtare T, Johnson CS, et al. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. The Prostate. 2011;71(4):368-72.
82. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & molecular immunology. 2020;17(5):533-5.
83. Moon C. Fighting COVID-19 exhausts T cells. Nature reviews Immunology. 2020;20(5):277.
84. Minton K. DAMP-driven metabolic adaptation. Nature reviews Immunology. 2020;20(1):1.
85. Xiao L, Sakagami H, Miwa N. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? Viruses. 2020;12(5):491.
86. van de Veerdonk F, Netea MG, van Deuren M, van der Meer JWM, de Mast Q, Bruggemann RJ, et al. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. 2020.
87. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6.
88. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? The Lancet Diabetes & Endocrinology. 2020.
89. Machado CDS, Ferro Aissa A, Ribeiro DL, Antunes LMG. Vitamin D supplementation alters the expression of genes associated with hypertension and did not induce DNA damage in rats. Journal of toxicology and environmental health Part A. 2019;82(4):299-313.
90. Gracia-Ramos AE. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection? Archives of medical research. 2020;51(4):345-6.